# Colorectal Cancer Treatments and Studies
**Type:** Topics
**Canonical URL:** https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/
## Facts
| Field | Value |
| --- | --- |
| Description | This cluster of papers represents advancements in the research and treatment of colorectal cancer, focusing on topics such as the use of cetuximab and bevacizumab, the impact of KRAS and BRAF mutations, the efficacy of chemotherapy, and the development of molecular subtypes for precision medicine. It also explores the role of EGFR inhibitors and the molecular mechanisms underlying metastatic colorectal cancer. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11067 |
| Works | 411 |
## Topic papers all
Showing 15 of 411.
- [EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy](https://scholariq.org/papers/i-egfr-i-mutations-in-lung-cancer-correlation-with-clinical-response-to/)
- [Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade](https://scholariq.org/papers/mismatch-repair-deficiency-predicts-response-of-solid-tumors-to-pd-1-blockade/)
- [Radiomics: the bridge between medical imaging and personalized medicine](https://scholariq.org/papers/radiomics-the-bridge-between-medical-imaging-and-personalized-medicine/)
- [Immune-Related Adverse Events Associated with Immune Checkpoint Blockade](https://scholariq.org/papers/immune-related-adverse-events-associated-with-immune-checkpoint-blockade/)
- [EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib](https://scholariq.org/papers/egf-receptor-gene-mutations-are-common-in-lung-cancers-from-never-smokers-and/)
- [A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.](https://scholariq.org/papers/a-national-cancer-institute-workshop-on-microsatellite-instability-for-cancer/)
- [Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability](https://scholariq.org/papers/revised-bethesda-guidelines-for-hereditary-nonpolyposis-colorectal-cancer-lynch/)
- [Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study](https://scholariq.org/papers/nivolumab-in-patients-with-metastatic-dna-mismatch-repair-deficient-or/)
- [Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine](https://scholariq.org/papers/adjuvant-chemotherapy-for-gastric-cancer-with-s-1-an-oral-fluoropyrimidine/)
- [Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer](https://scholariq.org/papers/japanese-society-for-cancer-of-the-colon-and-rectum-jsccr-guidelines-2016-for/)
- [Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)](https://scholariq.org/papers/memorial-sloan-kettering-integrated-mutation-profiling-of-actionable-cancer/)
- [Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis](https://scholariq.org/papers/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of-cetuximab-plus/)
- [Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer](https://scholariq.org/papers/durable-clinical-benefit-with-nivolumab-plus-ipilimumab-in-dna-mismatch-repair/)
- [Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer](https://scholariq.org/papers/japanese-society-for-cancer-of-the-colon-and-rectum-jsccr-guidelines-2019-for/)
- [Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/colon-cancer-version-2-2021-nccn-clinical-practice-guidelines-in-oncology/)
## Topic primary papers
Showing 15 of 112.
- [Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis](https://scholariq.org/papers/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of-cetuximab-plus/)
- [Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer](https://scholariq.org/papers/durable-clinical-benefit-with-nivolumab-plus-ipilimumab-in-dna-mismatch-repair/)
- [Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer](https://scholariq.org/papers/japanese-society-for-cancer-of-the-colon-and-rectum-jsccr-guidelines-2019-for/)
- [Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/colon-cancer-version-2-2021-nccn-clinical-practice-guidelines-in-oncology/)
- [KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors](https://scholariq.org/papers/kras-sup-g12c-sup-inhibition-with-sotorasib-in-advanced-solid-tumors/)
- [Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer](https://scholariq.org/papers/encorafenib-binimetinib-and-cetuximab-in-i-braf-i-v600e-mutated-colorectal/)
- [Colorectal cancer](https://scholariq.org/papers/colorectal-cancer-3/)
- [Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy](https://scholariq.org/papers/improved-survival-in-metastatic-colorectal-cancer-is-associated-with-adoption-of/)
- [Duration of Adjuvant Chemotherapy for Stage III Colon Cancer](https://scholariq.org/papers/duration-of-adjuvant-chemotherapy-for-stage-iii-colon-cancer/)
- [Colorectal cancer](https://scholariq.org/papers/colorectal-cancer-2/)
- [FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study](https://scholariq.org/papers/folfoxiri-plus-bevacizumab-versus-folfiri-plus-bevacizumab-as-first-line/)
- [Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer](https://scholariq.org/papers/initial-therapy-with-folfoxiri-and-bevacizumab-for-metastatic-colorectal-cancer/)
- [Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/dual-targeted-therapy-with-trastuzumab-and-lapatinib-in-treatment-refractory/)
- [A colorectal cancer classification system that associates cellular phenotype and responses to therapy](https://scholariq.org/papers/a-colorectal-cancer-classification-system-that-associates-cellular-phenotype-and/)
- [Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study](https://scholariq.org/papers/ramucirumab-versus-placebo-in-combination-with-second-line-folfiri-in-patients/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.